A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(18 sites)

United States

FOMAT Oncology, Oxnard, California

Cleveland Clinic Weston Hospital, Weston, Florida

Karmanos Cancer Institute, Detroit, Michigan

Hackensack Meridian Health-Southern Ocean Medical Center, Manahawkin, New Jersey

Cleveland Clinic, Cleveland, Ohio

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

TxO Central/South, Texas Oncology -Central/South Texas, Austin, Texas

Virginia Cancer Specialists, Fairfax, Virginia

China

Fujian Provincial Cancer Hospital, Fuzhou, Fujian

Wuhan Union Hospital, Wuhan, Hubei

Shanghai East hospital, Shanghai, Shanghai Municipality

Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality

France

Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou, Rennes, Ille-et-Vilaine

Centre Hospitalier Universitaire CHU De Limoges, Limoges, New Aquitaine

CHU Bordeaux - Centre Francois Magendie, Pessac, New Aquitaine

Centre Francois Baclesse, Caen, Normandy

CHU Toulon - Hopital Sainte Musse, Toulon, Var